Literature DB >> 22055835

The safety, efficacy and predictors for HbA1c reduction of sitagliptin in the treatment of Japanese type 2 diabetes.

Hajime Maeda1, Akira Kubota, Yasushi Tanaka, Yasuo Terauchi, Ikuro Matsuba.   

Abstract

We evaluated the efficacy and safety of sitagliptin after 3 months' treatment in Japanese type 2 diabetic patients and examined changes in clinical factors. Baseline HbA1c, PPG, BMI, and duration of diabetes may be predictors of HbA1c reduction when using sitagliptin in Japanese type 2 diabetic patients.
Copyright © 2011 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 22055835     DOI： 10.1016/j.diabres.2011.10.011

Source DB:  PubMed          Journal:  Diabetes Res Clin Pract        ISSN： 0168-8227            Impact factor:   5.602


  33 in total

1.  Long-term efficacy and safety of sitagliptin in the treatment of Japanese Type 2 diabetes (ASSET-K1) to a target of HbA1c <7%.

Authors:  H Maeda; A Kubota; A Kanamori; Y Tanaka; Y Terauchi; I Matsuba
Journal:  J Endocrinol Invest       Date:  2013-02-04       Impact factor: 4.256

2.  Sitagliptin counteracts seasonal fluctuation of glycemic control.

Authors:  Tomohiro Matsuhashi; Motoaki Sano; Keiichi Fukuda; Shun Kohsaka; Yoshihiko Suzuki
Journal:  World J Diabetes       Date:  2012-06-15

Review 3.  More than just an enzyme: Dipeptidyl peptidase-4 (DPP-4) and its association with diabetic kidney remodelling.

Authors:  Shreyasi Gupta; Utpal Sen
Journal:  Pharmacol Res       Date:  2019-08-08       Impact factor: 7.658

4.  Different effects of linagliptin and sitagliptin on blood pressure and renal function in Japanese patients with type 2 diabetes mellitus.

Authors:  Masayuki Tojikubo; Yuji Tajiri
Journal:  Diabetol Int       Date:  2017-04-24

5.  Pleiotropic effects of sitagliptin in the treatment of type 2 diabetes mellitus patients.

Authors:  Akira Kubota; Hajime Maeda; Akira Kanamori; Kiyokazu Matoba; Yasuyuki Jin; Fuyuki Minagawa; Mitsuo Obana; Koutarou Iemitsu; Shogo Ito; Hikaru Amemiya; Mizuki Kaneshiro; Masahiko Takai; Hideaki Kaneshige; Kazuhiko Hoshino; Masashi Ishikawa; Nobuaki Minami; Tetsuo Takuma; Nobuo Sasai; Sachio Aoyagi; Takehiro Kawata; Atsuko Mokubo; Hiroshi Takeda; Shin Honda; Hideo Machimura; Tetsuya Motomiya; Manabu Waseda; Yoshikazu Naka; Yasushi Tanaka; Yasuo Terauchi; Ikuro Matsuba
Journal:  J Clin Med Res       Date:  2012-09-12

6.  Two-year assessment of the efficacy and safety of sitagliptin in elderly patients with type 2 diabetes: Post hoc analysis of the ASSET-K study.

Authors:  Shinichi Umezawa; Akira Kubota; Hajime Maeda; Akira Kanamori; Kiyokazu Matoba; Yasuyuki Jin; Fuyuki Minagawa; Mitsuo Obana; Kotaro Iemitsu; Shogo Ito; Hikaru Amamiya; Mizuki Kaneshiro; Masahiko Takai; Hideaki Kaneshige; Kazuhiko Hoshino; Masashi Ishikawa; Nobuaki Minami; Tetsuro Takuma; Nobuo Sasai; Sachio Aoyagi; Takehiro Kawata; Atsuko Mokubo; Yukiko Miyairi; Hiroshi Takeda; Shin Honda; Hideo Machimura; Tetsuya Motomiya; Manabu Waseda; Yoshikazu Naka; Yasushi Tanaka; Yasuo Terauchi; Ikuro Matsuba
Journal:  BMC Endocr Disord       Date:  2015-07-03       Impact factor: 2.763

7.  Factors Predicting Therapeutic Efficacy of Combination Treatment With Sitagliptin and Insulin in Type 2 Diabetic Patients: The ASSIST-K Study.

Authors:  Masashi Ishikawa; Masahiko Takai; Hajime Maeda; Akira Kanamori; Akira Kubota; Hikaru Amemiya; Takashi Iizuka; Kotaro Iemitsu; Tomoyuki Iwasaki; Goro Uehara; Shinichi Umezawa; Mitsuo Obana; Hideaki Kaneshige; Mizuki Kaneshiro; Takehiro Kawata; Nobuo Sasai; Tatsuya Saito; Tetsuo Takuma; Hiroshi Takeda; Keiji Tanaka; Nobuaki Tsurui; Shigeru Nakajima; Kazuhiko Hoshino; Shin Honda; Hideo Machimura; Kiyokazu Matoba; Fuyuki Minagawa; Nobuaki Minami; Yukiko Miyairi; Atsuko Mokubo; Tetsuya Motomiya; Manabu Waseda; Masaaki Miyakawa; Yoshikazu Naka; Yasuo Terauchi; Yasushi Tanaka; Ikuro Matsuba
Journal:  J Clin Med Res       Date:  2015-06-09

8.  Factors involved in decreasing the therapeutic effect of sitagliptin: a subanalysis of the JAMP study.

Authors:  Hideo Nunome; Hiroshi Sakura; Naotake Hashimoto; Kazuo Sasamoto; Hiroshi Ohashi; Sumiko Hasumi; Noriko Ujihara; Tadasu Kasahara; Osamu Tomonaga; Masashi Honda; Yasuhiko Iwamoto
Journal:  Diabetol Int       Date:  2017-12-16

9.  Factors associated with reduced efficacy of sitagliptin therapy: analysis of 93 patients with type 2 diabetes treated for 1.5 years or longer.

Authors:  Akira Kanamori; Ikuro Matsuba
Journal:  J Clin Med Res       Date:  2013-04-23

10.  Predictive Factors for Efficacy of Dipeptidyl Peptidase-4 Inhibitors in Patients with Type 2 Diabetes Mellitus.

Authors:  Shusuke Yagi; Ken-Ichi Aihara; Masashi Akaike; Daiju Fukuda; Hotimah Masdan Salim; Masayoshi Ishida; Tomomi Matsuura; Takayuki Ise; Koji Yamaguchi; Takashi Iwase; Hirotsugu Yamada; Takeshi Soeki; Tetsuzo Wakatsuki; Michio Shimabukuro; Toshio Matsumoto; Masataka Sata
Journal:  Diabetes Metab J       Date:  2015-07-21       Impact factor: 5.376
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.